Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 11Adrenocortical Carcinoma 7Thyroid Carcinoma, Anaplastic 5Carcinoma, Neuroendocrine 4Thyroid Neoplasms 3Adrenal Cortex Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Carcinoma, Small Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Penile Neoplasms 1Pathologic Processes 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma 1Neoplasms, Unknown Primary 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1

Interventions

Magnetic Resonance Spectroscopy 9Iodine-131 7Thyrotropin Alfa 5trametinib 3lenvatinib 3cabozantinib 3Sunitinib 3Specimen Handling 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2dabrafenib 2X-Rays 2Trastuzumab 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Interviews as Topic 2Gefitinib 2Everolimus 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1tipifarnib 1tanespimycin 1spartalizumab 1selpercatinib 1sargramostim 1romidepsin 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Follicular × pembrolizumab × Endocrine × Clear all
NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Academic and Community Cancer Research United

Phase 2 Completed
57 enrolled 14 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡